Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

Ähnliche Einträge

• Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
  von: Platzbecker, Uwe, et al.
  Veröffentlicht: (2014)
• Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome: emphasis on optimized dosing schedules and new formulations
  von: Nolte, Florian, et al.
  Veröffentlicht: (2015)
• A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis
  von: Phatak, Pradyumna, et al.
  Veröffentlicht: (2010)
• Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
  von: Valent, Peter, et al.
  Veröffentlicht: (2017)
• Curcumin as an epigenetic therapeutic agent in myelodysplastic syndromes (MDS)
  von: Xie, Xiaoqing, et al.
  Veröffentlicht: (2022)